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Abstract
The development of alternative strategies to prevent HIV infection is a global public health priority. Initial efforts in anti-HIV
microbicide development have met with poor success as the strategies have relied on a non-specific mechanism of action.
Here, we report the development of a microbicide aimed at specifically blocking HIV entry by displaying molecular
components of the HIV/host cell attachment complex on the surface of Caulobacter crescentus, a harmless aquatic
bacterium. This bacterium can be readily manipulated to present heterologous proteins at high density on its surface by
genetic insertion into its crystalline surface layer protein [1,2]. In separate constructions, we generated bacteria displaying
domain 1 of CD4 and MIP1a. Each moiety reacted with specific antibodies by Western immunoblot and immuno-
fluorescence microscopy. Microbicide functionality was assessed using an HIV pseudotype virus assay system representing
Clade B subtypes. Bacteria displaying MIP1a reduced infectivity by 35–78% depending on the specific subtype while CD4
display reduced infection by as much as 56%. Combinations of both constructs reduced infectivity by nearly 98%. We
demonstrated that HIV infection could be inhibited using a strategy aimed at HIV-specific molecular interactions with
Caulobacter surface protein display, and that sufficient protein folding and conformation could be mimicked to bind and
block entry. Further, this is the first demonstration that Caulobacter surface protein display may be a useful approach to
preventing HIV infection or other viruses as a microbicide. We propose that this harmless bacterium, which is inexpensive to
produce and formulate, might be suitable for topical applications as a viable alternative in the search for effective
microbicides to counteract the world wide incidence of HIV infection.
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Introduction
Human Immunodeficiency Virus (HIV) is a growing epidemic
and one of the largest global health concerns in this present day.
UNAIDS 2008 Report estimated that over 32.9 million people
were living with HIV, 2.7 million people became infected in 2007,
and there were 2 million reported deaths that year [3]. Due to
difficulties in designing an effective HIV vaccine as a consequence
of the genetic diversity of the virus, current research has been
focusing on the development of microbicides.
In developing countries, women are 3–6 times more likely to
become infected with HIV than men due to a lack of female-
controlled methods to prevent the transmission of the virus [4]. In
women, the main site of HIV entry is the cervicovaginal mucosa.
Although the precise cell type and transmission site are not
completely understood, it is believed that an appropriately
manufactured microbicide will be beneficial as it will offer broad
protection against mucosal transmission of HIV at the point of
entry. Currently, there are no microbicides on the market but as
many as 50 different drugs are currently being tested in clinical
trials [5]. Typical methods of delivery include semi-solid aqueous-
based gels, vaginal rings, quick-dissolve films, and vaginal tablets
[5]. To date, microbicides have shown potential in blocking HIV
in tissue culture, but have failed to protect in clinical trials. The
primary strategy and likely failing of these early microbicide
products is their non-specific mode of action.
Efforts to produce specific microbicide blocking agents using
whole organisms have centered on the construction of commensal
bacteria, such as Lactobacillus, that would display HIV blocking
abilities while colonizing the vaginal mucosa [6,7,8]. Inherent in
these approaches is the expectation that sufficiently high levels of
these bacteria can successfully compete with other microbial flora
and thereby be continuously maintained at mucosal surfaces at
useful levels for extended periods of time. While competing for
space in the microflora population of the vaginal mucosa, these
bacteria would also be required to maintain sufficiently high
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as CD4 on the bacteria to effectively block HIV infection.
As a contrast to this approach, we developed a bacterium based
microbicide display option that does not rely on the bacterium’s
ability to compete and survive within the microflora. Caulobacter
crescentus is not a commensal bacterium; it does not grow at
temperatures exceeding ca 32uC and will not grow in the presence
of salts at levels typical for sera. But it is capable of display of
proteins at very high levels and surface densities. It can be
cultivated readily to high densities on defined growth media
consisting only of glucose and essential inorganic ions. Although a
gram negative organism, its unusual lipopolysaccharide structure
appears to have a much reduced sepsis potential, relative to enteric
bacteria [9]. With these characteristics we expect the possibility
that engineered strains can be formulated to be applied as
stabilized killed organisms, designed to be applied to vaginal or
other mucosal tissues at relevant times, such prior to sexual acts or
childbirth, roughly comparable to spermicide use. This permits
maintenance of high levels without the requirement for, or
potential negative effects of competition with the existing
microflora.
Given the display capabilities of C. crescentus we envision the
development of a variety of agents expected to interrupt the HIV
infection process, and then to apply several simultaneously, to
enhance microbicide effects and to minimize the possibility of
development of resistance. This includes antibodies directed to
HIV gp120, mimics for host receptors and co-receptors for HIV
engagement, as well as the ligands for these surface proteins or
structural analogues for any of the above. Here we begin with
display of domain 1 of CD4, the HIV receptor and MIP1a, the
ligand for CCR5, the HIV co-receptor. Considerable evidence
exists that demonstrates that binding to block either of these two
ligand interactions (CD4:gp120 and MIP1a:CCR5) will inhibit
HIV infection [10]. Herein, we demonstrate that separate
constructs have the ability to significantly block infection and that
the application of both simultaneously has additive microbicide
effects.
Materials and Methods
Bacterial strains, growth conditions and general plasmid
related methods
Escherichia coli strain DH5 a (Invitrogen, Carlsbad, CA) was
grown at 37uC in Luria Broth (1% tryptone, 0.5% NaCl, 0.5%
yeast extract), adding 1.3% agar for plates. The C. crescentus strain
JS 4022 [11]was propagated in PYE medium (0.2% peptone,
0.1% yeast extract, 0.01% CaCl2, 0.02% MgSO4), at 30uC. For
growth on solid medium, agar was added to 1.3%.
Where necessary, media contained chloramphenicol (CM) at
20 mg/ml (E. coli)o r2mg/ml (C. crescentus). Electroporation of C.
crescentus was performed as previously described [12]. The Nucleic
Acid Protein Service unit of the University of British Columbia
provided oligonucleotide synthesis and DNA sequencing. Plasmid
DNA was isolated using a QIAprep miniprep plasmid isolation kit
(QIAGEN), and DNA fragments were recovered from agarose gels
using a QIAEX II gel extraction kit (QIAGEN). PCR products
were generated using Pfx DNA polymerase (Invitrogen, Carlsbad,
CA), following the manufacturer’s protocol.
Preparation of C. crescentus displaying chimeric S-layer
proteins
pT4B (CD4 in pSP65, [13], (obtained from the AIDS Research
and Reference Reagent Program, Div. of AIDS, NIAID, NIH:
pTB4B from Dr. Richard Axel)) was used as a template and the
oligos JN CD4-1 59GGA AGA TCT ACT AGT GGG GAT ACA
GTG GAA CTG ACC39 and JN CD4-2 59GGG GCT AGC
CTG GTC CTC CAC TTC ACA GAT39 were used in a PCR
reaction to make the DNA fragment that codes for the 81 amino
acid CD4 domain 1 segment (GDTVELTCTASQKKSIQ-
FHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWD-
QGNFPLIIKNLKIEDSDTYICEVEDQ). Similarly, pCDNA3
CCL3 L1 [14] was used as template and the oligos JN CCR5-1
59GGA AGA TCT ACT AGT GCA CCA CTT GCT GCT
GAC ACG CCG39 and JN CCR5-2 59CGG GCT AGC ACT
CAG CTC CAG GTC ACT GAC39 were used to make the DNA
fragment that codes for the 70 amino acid MIP1a segment
(APLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPSVI-
FLTKRGRQVCADPSEEWVQKYVSDLELSA). The DNA seg-
ments produced contained BglII and SpeI restriction sites on the 59
end and an NheI site on the 39 end. The restriction sites
arrangement allowed the segments to be directionally cloned into
p4ARsaA(723)/GSCC digested with BglII and NheI [11].
Following ligation plasmids were introduced into E. coli by
electroporation. Plasmids were retrieved from selected clones and
the inserted sequence confirmed by DNA sequencing before
transfer to C. crescentus JS4022 by electroporation. The result was
the in-frame introduction of the CD4 and MIP1a segments at a
site corresponding to amino acid 723 of the native RsaA protein.
p4ARsaA(723) (containing only a BamH1 restriction site at the
same position) was used as a negative control. Hereafter, the
Caulobacter constructs will be referred to as the Cc-CTRL, Cc-
CD4 or Cc-MIP1a clones.
Heat-inactivated Caulobacters were prepared by treatment of
cultures at 70uC for 4 minutes; killing was confirmed by spread
plating.
Fluorescence microscopy
Antibodies to CD4 (murine monoclonals SIM.2 and SIM.4 and
polyclonal sheep anti-human CD4) and MIP1a (polyclonal goat
anti-Mip1a) were obtained from the NIH AIDS Reagent and
Reference Program. To confirm the presence of displayed proteins
on Caulobacter, in a typical experiment 30 ml of cells and 1–5 ml
of antibodies were diluted to 200 ml in PYE medium and
incubated in ice for 30 min. The mixture was diluted to 1.7 ml
with PYE medium and centrifuged at 13,0006g for 4 min. Cell
pellets were suspended in 100 ml of PYE and 1 ml anti-mouse, anti-
goat or anti-sheep antisera coupled to Alexa488 (Molecular
Probes/Invitrogen). After a 20 min on ice the mixture was diluted
to 1.7 ml and centrifuged. Pellets were suspended in 20 mM
phosphate buffer containing 50% glycerol and 2% n-propyl gallate
and examined by epifluorescence microscopy.
Protein analysis
S-layer and S-layer recombinant proteins were recovered from
the cell surface by low-pH extraction method, as described
previously [15] Proteins were visualized using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) using
7.5% separating gels and staining with Coomassie brilliant blue R.
Preparation of Caulobacter cells for binding assay.
Caulobacter strain JS4022 with different plasmids were grown
in 10 ml PYE medium to an optical density of approximately 1.0
at 600 nm (3.1610
9 cells/ml). Cells were centrifuged and
suspended in 10 mM potassium phosphate buffer (pH 7.0).
This was repeated and cells were re-suspended in 1 ml of the
same. Cell density was adjusted to 1610
10 cells/ml for binding
experiments.
Microbicide Inhibition of HIV
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pseudotype analysis
E. coli with plasmids containing the viral DNA cassettes were
grown overnight at 37uC in LB broth containing 50 mg/ml of
ampicillin. The DNA from the rev/env clones as well as the HIV-
env-deficient (SG3Denv) backbone from the standardized subtype
B HIV-1 panel (NIH AIDS Reagent and Reference Program) was
then purified using the Sigma GenElute HP Plasmid MaxiPrep
Kit. DNA was further purified with two phenol-chloroform
extraction steps followed by ethanol precipitation and suspension
in 10 mM Tris buffer (pH 7.5) containing 1 mM EDTA. The final
concentration of the DNA was determined by spectroscopy at
260 nm.
The clade B HIV-1 panel (NIH AIDS Reagent and Reference
Program) [16], consists of virus clones SVPB11 (PVO, clone4),
SVPB12 (TRO, clone 11), SVPB13 (AC10.0, clone29), SVPB14
(pRHPA4259, clone 7), SVPB15 (pTHRO4156, clone 18), and
SVPB16 (pREJO4541, clone 67).
Two days prior to transfection, 2.6610
6 293T cells were
seeded in a 10 cm corning plate, using either complete DMEM
(1% Penicillin/Streptomycin and 7.5% FBS) or in medium
lacking antibiotics. Transfection was performed using Lipofecta-
mine (Invitrogen) diluted 1:3 in serum free medium. This was
followed by the addition of the rev/env clone (12 mg) and the
HIV-1 env-deficient backbone (24 mg). After a 20 min incubation
at 37uC and 5% CO2, the mixture was added to the 293T cells,
followed by another incubation period of 48 h. In order to
provide necessary growth conditions, 15 ml of serum free
medium was added to the cells at 4 hours post transfection.
The virus was then harvested and collected using a 0.45 mm
syringe filter and stored at 280uC.
Virus Titration
Titrations were performed to determine the amount of virus
produced during the transfection. This assay was done using
TZM-bl cells, which are derived from HeLa cells and
engineered to express HIV receptors such as CD4 and CCR5
[17]. These cells also contain the luciferase and beta-galacto-
sidase genes under the control of the HIV-1 long terminal
repeat [18]. Serial dilutions of virus were prepared in 96 well
plates using medium containing 75 mg/ml of DEAE-dextran.
Previously prepared TZM-bl cells were added to each well for a
final concentration of 200 cells/ml. The titration plate was then
maintained for 48 h at 37uCa n d5 %C O 2. Infection of cells was
measured indirectly using a Mammalian b-galactosidase assay
kit (PIERCE) followed by an absorbance reading at 415l.A n
absorbance of greater than 0.2, was considered a positive
infection. The Tissue Culture Infectious Dose (TCID50) was
determined for each viral stock per 1 ml by identifying the
dilution of virus in which 50% of the TZM-bl cells were
infected, as measured by the presence of b-galactosidase. It was
determined that doses of 200 TCID50 were sufficient for
experimentation and the virus was stored at 280uC.
Virus blocking experiments
The Cc-CTRL (no insert), Cc-CD4, and Cc-MIP1a Caulo-
bacter constructs were grown and prepared one day prior to an
experiment. Experiments were carried out in triplicate wells of
96 well plates (at 3 identical wells per experimental condition)
using Caulobacter at a concentration of 10
8,1 0
7,a n d1 0
6 cells/
ml. The TZM-bl cells were prepared in a manner as previously
described. The volume of virus added was determined by
previously calculating the 200TCID50 value. The virus was
incubated for 1 h with the CD4 construct before the addition of
TZM-bl cells. This allows sufficient binding of the bacteria to its
predicted targets. In contrast, the MIP1a and control constructs
were first exposed to TZM-bl cells for 1 h prior to virus
addition. It was also necessary to determine the percent of
infectivity when two of the constructs were combined (Cc-CD4
and Cc-MIP1a) and in this instance, both recombinant
caulobacters were incubated to cells first and virus added 1 h
later. After an overnight incubation at 37uCi n5 %C O 2,t h e
plates were centrifuged at 800 rpm for 5 min and medium was
changed in all wells. 48 h after initial incubation the viral titer
was analyzed as previously described. As a positive control for
inhibition of infection, the HIV gp120 specific monoclonal
antibody, 2F5 was added to the assay of each experiment in
triplicate. Data are presented and determined as a percentage of
infection of the untreated control infection wells with the
background from uninfected subtracted out.
Statistical analysis
Statistical analysis was performed with Prism GraphPad
software. The unpaired Student’s t-test was used for statistical
analysis. A P value of less than 0.05 was considered significant and
values are reported in the respective legends.
Figure 1. Display of CD4 domain 1 on Caulobacter. A. SDS-PAGE
of normalized low pH extraction of S-layer protein (RsaA) from C.
crescentus JS 4022. Lane 1- RsaA obtained from Cc-CTRL. Lane 2- RsaA
obtained from Cc-CD4. Asterisks indicate the RsaA proteins. B.
Fluorescence microscopy using anti-CD4 polyclonal antibody and an
Alexa488-labeled secondary.
doi:10.1371/journal.pone.0010366.g001
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Expression of MIP1a and single domain CD4,
independently within the S-layer protein of Caulobacter
To generate recombinant Caulobacter with expression of
heterologous proteins within its surface S-layer protein, two
separate vectors expressing either MIP1a or a single domain of
CD4 were generated using p4ARsaA(723)/cmyc, an expression
vector for C. crescentus, containing a version of rsaA (the S-layer
gene) carrying restriction sites for insertion of genetic material at a
site corresponding to amino acid 723 of the S-layer protein [11].
Using SDS-PAGE, we determined that both recombinant vectors
(Cc-MIP1a, Cc-CD4) successfully generated chimeric S-layer
proteins following transformation into C. crescentus (Fig. 1, 2).
Further, immunofluorescent staining and microscopy of the
recombinant Caulobacters with antibodies specific for MIP1a or
CD4 demonstrated uniform staining across the bacterial cell
surface, including the cell stalk, consistent with a complete
coverage of the cell with the modified S-layer (Fig. 1, 2). Notably,
immunostaining of C. crescentus expressing the single domain CD4
with the conformation dependent antibodies, SIM.2 and SIM.4,
demonstrated proper conformation of the CD4 structure on the
surface and this strongly suggested binding capability for gp120. In
all cases, immunostaining of Caulobacters displaying an RsaA with
no genetic insertion gave a negative result (not shown).
Inhibition of HIV-1 infection with recombinant
Caulobacter expressing either MIP1a or single domain
CD4 with the S-layer
To determine whether expression of either MIP1a or single
domain CD4 was sufficient to block infection of HIV-1, the
recombinant C. crescentus were co-incubated with pseudotyped
HIV-1 and TZM-bl cells in standard single cycle infection assays.
Our initial studies with a single member of the clade B reference
strain SVPB13, showed significant inhibition with both constructs
(Figure 3) and warranted further study using the complete clade B
reference panel from the NIH AIDS Research and Reference
Reagent Program. We compared the ability of the two
recombinant Caulobacters to inhibit different strains of HIV and
better evaluate the potential general effectiveness of these specific
reagents as potential microbicides (Figure 4).
Cc-MIP1a provided statistically significant protection from
infection when compared to the Cc-CTRL (lacking MIP1a
expression) (Figure 3, 4). Depending on the reference HIV-1
clone, the block in infection ranged from 35–78%. Co-incubation
with Cc-CD4 also varied depending on the reference HIV-1 clone
and effectively blocked from 22–56% of infection. Effective
inhibition by Cc-MIP1a was not observed in 1 of the reference
clones. The observed variability was likely due to the variation in
gp120 sequence across the panel of HIV-1 clones as previously
reported by Li et al. using both monoclonal antibody and soluble
CD4 inhibitors [16].
Comparing heat inactivated Caulobacter to recombinant
Caulobacter
Continued development of this approach as a microbicide agent
will likely involve the use of inactivated bacteria. Although
inhibition had been demonstrated with co-incubation with live
Caulobacter, the environmental conditions of the assay did not
promote Caulobacter growth and survival. To preliminarily test
the effectiveness of inactivated Caulobacter on inhibition of HIV-1
infection, the recombinant bacteria were heat inactivated (HIC)
prior to co-incubation in the single cycle assays. Both Cc-MIP1a
and CC-CD4 were found to effectively inhibit HIV-1 infection
Figure 2. MIP1a surface display on Caulobacter. A. SDS-PAGE of normalized low pH extraction of S-layer protein (RsaA) from C. crescentus JS
4022. Lane 1- RsaA obtained from Cc-CTRL. Lane 2 - RsaA obtained from Cc-MIP1a. B. Fluorescence microscopy using anti-MIP1a polyclonal antibody
and an FITC-labeled secondary.
doi:10.1371/journal.pone.0010366.g002
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Caulobacter was found to be more effective at inhibiting infection
following heat inactivation.
Combinatorial effects on HIV-1 inhibition of co-
incubation with Cc-MIP1a and Cc-CD4
It is likely that to achieve the broadest and most effective
inhibition of HIV-1 infection a cocktail of several recombinant
Caulobacters expressing different infection blockers will be
required. To test the effectiveness of a cocktail strategy, co-
incubation of Cc-MIP1a and Cc-CD4 with the pseudotyped
HIV-1 and TZM-bl cells in single infection assays was
performed. Co-incubation with both recombinant reagents
demonstrated statistically significant enhanced blocking abili-
ties against all reference strains tested, ranging from 74–98%
inhibition of infection (Figure 6). Interestingly, against specific
clade representatives like SVPB16, the individual recombinant
Caulobacters poorly inhibited, yet in combination infection
was reduced more than 80%. In no case was the combination
of constructs observed to inhibit less than that observed for the
individual recombinants. This observed enhancement validates
the view that an effective microbicide would consist of multiple
combinations of specific binding to maximally inhibit HIV
infection.
Discussion
The primary question posed in this study was whether the
innocuous bacterium C. crescentus and its ability to display relatively
large protein segments could be used to devise HIV specific
blocking agents by mimicking the ligands involved with the
interaction of the virus with its host cell. This minimally required
success in achieving secretion of the chimeric S-layer protein,
dense surface display and correct folding of the displayed
segments. This was achieved and we were able to block infection
in the standard TZM-bl assay for lentiviral infection by either
blocking the host cell co-receptor (via MIP1a display) or the virus
itself, via CD4 display. Each performed this function separately,
reducing infectivity by about half and when the two constructs
were combined into one assay infection inhibition worked in an
additive fashion, achieving nearly complete blockage.
It is reasonable to presume that correct or nearly correct folding
occurred for both MIP1a and CD4 when displayed on
Caulobacter, given the ability to bind specific antibodies and the
infection blocking activity noted. It is also highly likely that the
high level expression and the S-layer mediated display of the
ligands compensated for any less than perfect folding by providing
multiple binding opportunities. Normal levels of Caulobacter S-
layer protein are unusually high for a bacterium (approximately
25% of total cell protein (manuscript submitted)). In this instance
we calculate that even the displayed recombinant portion alone
accounts for 1–2% of total cell protein and all of this is displayed
on the outermost surface of the bacterium. Thus, we expect that
the number of cells required to achieve a practical level of
inhibition of infection is likely significantly less than the lower level
display of CD4 reportedly observed on other bacteria such as
Lactobacilli [6,7,8,19].
Figure 3. Surface expression of MIP1a or CD4 on Caulobacter is
sufficient to inhibit infection with pseudotype HIV-1 subtype B
virus clone SVPB13. The recombinant Caulobacters were co-incubated
with HIV pseudotype virus SVPB13 and TZM-bl cells to demonstrate
inhibition of infection. TZM-bl cells were also incubated alone, with virus,
or with virus and neutralizing monoclonal antibody. Pseudotype virus
infection was measured by ELISA for b-galactosidase. Significant levels of
inhibition of infection were observed (denoted by asterisks) between both
Cc-MIP1a and the Cc-CTRL (,0.001) and Cc-CD4 and Cc-CTRL (,0.01). HIV
infections are presented as a percentage of the untreated control
infections using the same pseudotype virus, SVPB13 and with the
background for uninfected cells subtracted out. Each separate experiment
was performed with 3 assay wells per condition. Data represent mean +
standard error of the mean (s.e.m) from 4 separate experiments.
doi:10.1371/journal.pone.0010366.g003
Figure 4. Surface expression of MIP1a or CD4 on Caulobacter is
sufficient to inhibit infection with a number of pseudotype
HIV-1 subtype B viruses. The recombinant Caulobacters were co-
incubated with one of six different HIV pseudotype viruses and TZM-bl
cells to demonstrate inhibition of infection. TZM-bl cells were also
incubated alone, with virus, or with virus and neutralizing monoclonal
antibody. Pseudotype virus infection was measured by ELISA for b-
galactosidase. Significant levels of inhibition of infection were observed
between both Cc-MIP1a and the Cc-CTRL (,0.001 for all the
pseudotype clones) and Cc-CD4 and Cc-CTRL (,0.001 for SVPB11,
SVPB13, SVPB14, SVPB16 and ,0.01 for SVPB12, and SVPB15). HIV
infections are presented as a percentage of the untreated control
infections using the same pseudotype virus and with the background
for uninfected cells subtracted out. Each separate experiment was
performed with 3 assay wells per condition. Data represent mean +
s.e.m from 3–4 separate experiments.
doi:10.1371/journal.pone.0010366.g004
Microbicide Inhibition of HIV
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10366Variation in inhibition was observed across the different HIV-1
reference strains. Notably, the greatest variability was found
against the MIP1a construct and this is likely due to the high
degree of variability across gp120 for the individual pseudoviruses.
Prior work by Li et al. [16] demonstrated that across these 6
pseudovirus and a number of others that a significant level of
sequence variation exists and this variation is directly responsible
for differences in sensitivity and resistance of these viruses to env-
based neutralization. Prior to MIP1a binding to CCR5, proper
engagement of CD4 and gp120 followed by a folding event is
required to expose the full binding site. This complex binding
likely challenges the specific interactions of MIP1a with HIV env.
To develop the most effective measure, it is likely that a cocktail of
multiple recombinant Caulobacters expressing different HIV-1
blocking agents will inhibit the widest range of potential HIV-1
variants. This was clearly effective in our system as combinations
of both recombinant Caulobacters resulted in nearly complete
inhibition of infection.
The development of a bacteria based microbicide has an
expectation that the supply of cells is relatively inexpensive to
produce. Caulobacters are in fact simple to grow and can be
readily fermented to high densities in shake flasks or standard
fermenters in media containing only glucose, salts and ammonia as
a nitrogen source. As such, the development of Caulobacter as a
microbicide platform is a sound low cost choice in terms of
productivity. An important issue is whether Caulobacter is safe for
exposure to mucosal tissues. This has not yet been tested directly,
but the low endotoxin LPS [9] and the record of no septic or other
overt symptoms with intraperitoneal injections in mouse model
systems [20] suggests that it will be and that experiments to
determine safety are warranted.
The presumption in the use of engineered Caulobacters as a
microbicide is that it would not be used as a commensal bacterium
but rather as an agent that would be applied as a topical agent
prior to any perceived exposure or risk for infection (typically
through sexual acts or the process of childbirth with an HIV
positive mother). Caulobacters are not normal inhabitants of
humans and will not grow in this environment. As such, they are
merely a platform for the generation and presentation of the
blocking agent. Thus, this obviates any immediate concerns that
would be common to the use of a commensal bacterium for this
purpose - that is, being able to compete with normal flora or
alternatively, if it can compete, that long-term maintenance may
result in unwanted effects that are then difficult to reverse. Further,
it is our expectation that killed Caulobacters will be used.
Ultimately, this will be performed via heat, irradiation or
chemicals such as formalin or beta-propriolactone. In preliminary
studies with heat killed cells, blocking activity was relatively similar
to that observed for live cells, except that heat inactivated control
cells had an unexpectedly high level of inherent blocking activity.
This non-specific effect may be helpful (additive) to the specific
blocking ligands, or may be an indication that other killing
methods will be more appropriate and is currently under
investigation.
The exceptional ability of Caulobacter to tolerate the insertion
of a range of heterologous peptides and proteins in to its S-layer
structure has been demonstrated here and previously [2,11,21].
Figure 5. Heat inactivation of the recombinant Caulobacters
retains inhibition of infection for pseudotype HIV-1 subtype B
virus clone SVPB13. The recombinant Caulobacters were heat
inactivated and co-incubated with HIV pseudotype virus SVPB13 and
TZM-bl cells to demonstrate inhibition of infection. TZM-bl cells were
also incubated alone, with virus, or with virus and neutralizing
monoclonal antibody. Pseudotype virus infection was measured by
ELISA for b-galactosidase. Significant levels of inhibition of infection
were observed (denoted by asterisks) between HIC Cc-MIP1a and Live
Cc-MIP1a (,0.005), HIC Cc-CTRL and Live Cc-CTRL (,0.001), and HIC Cc-
CD4 and Live Cc-CD4 (,0.001). HIV infections are presented as a
percentage of the untreated control infections using the same
pseudotype virus, SVPB13 and with the background for uninfected
cells subtracted out. Each separate experiment was performed with 3
assay wells per condition. Data represent mean + s.e.m from 3 separate
experiments.
doi:10.1371/journal.pone.0010366.g005
Figure 6. Incubation of both recombinant Caulobacters with
pseudotype HIV-1 shows combinatorial effects and heightened
inhibition of infection against the clade B viruses. The
recombinant Caulobacters were combined in equal amounts and co-
incubated with one of six different HIV pseudotype viruses and TZM-bl
cells to demonstrate inhibition of infection. TZM-bl cells were also
incubated alone, with virus, or with virus and neutralizing monoclonal
antibody. Pseudotype virus infection was measured by ELISA for b-
galactosidase. Significant levels of inhibition of infection were observed
between both Cc-MIP1a/Cc-CD4 and the Cc-CTRL (,0.01 for all six
pseudotype viruses). HIV infections are presented as a percentage of
the untreated control infections using the same pseudotype virus and
with the background for uninfected cells subtracted out. Each separate
experiment was performed with 3 assay wells per condition. Data
represent mean + s.e.m from 3–4 separate experiments.
doi:10.1371/journal.pone.0010366.g006
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PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10366The ability of the native binding sites to remain intact following
display was further described. Our future work is not limited to
single constructs, as simultaneously expression of two or more
modified S-layers is readily possible [22]. When considering pairs
of displayed proteins, some are predicted to be potentially
synergistic with current two activities and other agents, such as
single chain antibodies directed to gp120 (for pairing with CD4
display) or ligands or antibodies directed to other T-cell or
mucosal cell receptors for pairing with MIP1a. The ultimate goal
is to produce the best combination of single and co-displayed
ligands to maximize HIV infection inhibition and to minimize the
opportunity to select for HIV isolates that evade the blocking
activity by mutation. An additional benefit in evaluating
combinations of ligands may be in discovering unexpected
synergistic infection inhibition, such as was noted with SVPB16.
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